CHEERS-AI Economic Evaluation

By João L. Carapinha

November 5, 2024

NICE (National Institute for Health and Care Excellence) introduces CHEERS-AI! It’s a new reporting standard optimized for health economic evaluations of AI technologies in healthcare. The EU funded CHEERS-AI as part of the Next Generation Health Technology Assessment (HTx) project. Its primary aim is to enhance the transparency and quality of cost-effectiveness studies specifically tailored for AI-enabled healthcare interventions.

Purpose and Background

CHEERS-AI seeks to systematically address the challenges facing health economic evaluations of AI interventions. A systematic review has identified several issues, including poor quality input data, author conflicts of interest, lack of transparent reporting, and vague information regarding AI functionality.

Solution: CHEERS-AI economic evaluation

Building on the established CHEERS 2022 standards, CHEERS-AI incorporates the original 28 standards while adding 8 new details for AI-related nuances and 10 AI-specific standards. The extra standards tackle key aspects such as user autonomy, continuous AI learning, and the methodology behind developing the AI component.

Objectives

The primary goal of CHEERS-AI is to ensure transparent and reproducible reporting of AI-specific details in health economic evaluations. This standard will aid healthcare decision-makers in understanding the value of AI-enabled treatments, ultimately facilitating faster access to promising AI technologies for patients.

Endorsement and Integration

ISPOR endorsed CHEERS-AI and is now included in the EQUATOR Network checklist of reporting guidelines. This endorsement ensures integration into best practices for health economic evaluation reporting.

Impact

Refining the quality and transparency of health economic evaluations involving AI technologies is an important objective. In doing so, CHEERS-AI aims to elevate the standards of economic evaluation reporting. This improvement is vital for reimbursement decisions and the broader adoption of AI in healthcare.

In summary, CHEERS-AI represents an advancement in standardizing and enhancing health economic evaluations of AI technologies, thereby supporting improved decision-making in healthcare.

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.